PMID- 35760057
OWN - NLM
STAT- MEDLINE
DCOM- 20221027
LR  - 20230701
IS  - 1423-0135 (Electronic)
IS  - 1018-1172 (Print)
IS  - 1018-1172 (Linking)
VI  - 59
IP  - 5
DP  - 2022
TI  - Apolipoprotein A-I Inhibits Transendothelial Transport of Apolipoprotein 
      B-Carrying Lipoproteins and Enhances Its Associated High-Density Lipoprotein 
      Formation.
PG  - 275-287
LID - 10.1159/000525259 [doi]
AB  - Caveola-located scavenger receptor type B class I (SR-BI) and activin 
      receptor-like kinase-1 (ALK1) are involved in transendothelial transport of 
      apolipoprotein B-carrying lipoproteins (apoB-LPs). Transport of apoB-LPs though 
      mouse aortic endothelial cells (MAECs) is associated with apoE-carrying 
      high-density lipoprotein (HDL)-like particle formation and apoAI induces 
      raft-located proteins to shift to non-raft membranes by upregulation of 
      ATP-binding cassette transporter A1 (ABCA1). To investigate apoAI's effect on 
      transendothelial transport of apoB-LPs, MAECs and human coronary artery 
      endothelial cells (HCAECs) were treated with apoB-LPs +/- apoAI. Our data 
      demonstrated that apoAI neither altered SR-BI and ALK1 expression nor affected 
      apoB-LP binding to MAECs. ApoAI inhibited MAEC uptake, transcellular transport, 
      and intracellular accumulation of apoB-LPs and accelerated their resecretion in 
      MAECs. ApoAI enhanced transendothelial apoB-LP transport-associated HDL-like 
      particle formation, upregulated ABCA1 expression, shifted SR-BI and ALK1 to the 
      non-raft membrane in MAECs, inhibited transcellular transport of apoB-LPs, and 
      enhanced associated HDL-like particle formation in HCAECs. ABCA1 knockdown 
      attenuated apoAI-induced membrane SR-BI and ALK1 relocation and diminished 
      apoAI's effect on transendothelial apoB-LP transport and HDL-like particle 
      formation in MAECs. This suggests that upregulation of ABCA1 expression is a 
      mechanism, whereby apoAI provokes caveola-located receptor relocation, inhibits 
      transendothelial apoB-LP transport, and promotes associated HDL-like particle 
      formation.
CI  - (c) 2022 S. Karger AG, Basel.
FAU - Guo, Zhongmao
AU  - Guo Z
AD  - Department of Microbiology, Immunology and Physiology, Meharry Medical College, 
      Nashville, Tennessee, USA, zguo@mmc.edu.
FAU - Zhang, Ningya
AU  - Zhang N
AD  - Department of Microbiology, Immunology and Physiology, Meharry Medical College, 
      Nashville, Tennessee, USA.
FAU - Yang, Hong
AU  - Yang H
AD  - Department of Microbiology, Immunology and Physiology, Meharry Medical College, 
      Nashville, Tennessee, USA.
LA  - eng
GR  - G12 MD007586/MD/NIMHD NIH HHS/United States
GR  - SC1 HL101431/HL/NHLBI NIH HHS/United States
GR  - U54 MD007586/MD/NIMHD NIH HHS/United States
GR  - U54 MD007593/MD/NIMHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220627
PL  - Switzerland
TA  - J Vasc Res
JT  - Journal of vascular research
JID - 9206092
RN  - EC 2.7.11.30 (Activin Receptors)
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Apolipoproteins E)
RN  - 0 (ATP Binding Cassette Transporter 1)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Receptors, Scavenger)
RN  - 0 (ABCA1 protein, human)
RN  - 0 (ABCA1 protein, mouse)
RN  - 0 (SCARB1 protein, human)
RN  - 0 (Scarb1 protein, mouse)
RN  - EC 2.7.11.30 (ACVRL1 protein, human)
RN  - EC 2.7.11.30 (Acvrl1 protein, mouse)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - Activin Receptors/metabolism
MH  - *Apolipoprotein A-I/pharmacology
MH  - *Apolipoproteins B/pharmacology
MH  - Apolipoproteins E
MH  - *ATP Binding Cassette Transporter 1/metabolism
MH  - ATP-Binding Cassette Transporters/metabolism
MH  - *Endothelial Cells/metabolism
MH  - Lipopolysaccharides
MH  - *Lipoproteins, HDL/metabolism
MH  - Receptors, Scavenger/metabolism
MH  - Caveolae/metabolism
MH  - Coronary Vessels/metabolism
PMC - PMC9847247
MID - NIHMS1817007
OTO - NOTNLM
OT  - Apolipoprotein A-I
OT  - Endothelial cell
OT  - High-density lipoprotein
OT  - Membrane microdomain reorganization
OT  - Transendothelial lipoprotein transport
COIS- Conflicts of interest The authors have no conflicts to disclose.
EDAT- 2022/06/28 06:00
MHDA- 2022/10/25 06:00
PMCR- 2023/06/27
CRDT- 2022/06/27 18:30
PHST- 2021/11/13 00:00 [received]
PHST- 2022/05/19 00:00 [accepted]
PHST- 2022/06/28 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/06/27 18:30 [entrez]
PHST- 2023/06/27 00:00 [pmc-release]
AID - 000525259 [pii]
AID - 10.1159/000525259 [doi]
PST - ppublish
SO  - J Vasc Res. 2022;59(5):275-287. doi: 10.1159/000525259. Epub 2022 Jun 27.